25 news items
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
CADL
FGEN
ONCY
12 Jun 24
. The main goals are to measure how well the treatments work and their safety. Additionally, the study will look at progression-free survival (how long
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
CADL
FGEN
ONCY
12 Jun 24
and atezolizumab. The main goals are to measure how well the treatments work and their safety. Additionally, the study will look at progression-free survival (how
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
REGN
11 Jun 24
finding and safety study in pediatric patients with pJIA. People living with pJIA may experience joint symptoms such as pain, stiffness
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
ABBV
FDMT
REGN
7 Jun 24
to the high standards of efficacy and safety set by newer anti-VEGF treatments that require fewer injections, e.g., high dose Regeneron
What's Going On With FibroGen Stock Tuesday?
FGEN
REGN
4 Jun 24
Gal9 levels of expression. Phase 1 trials evaluating the safety and efficacy of FG-3165 in patients with select solid tumors are expected to begin
qbl2 96dfvdtu16xzcdl9ghmj4s112mbt2gtl3
FGEN
REGN
3 Jun 24
trials evaluating the safety and efficacy of FG-3165 in patients with select solid tumors is expected to begin enrollment in the second half of 2024
1bmd7hms83a87fu a1bjnynuzi4wqdtjtss24q04rbr6o1
REGN
SNY
31 May 24
and NOTUS phase 3 studies, which evaluated the efficacy and safety of Dupixent in adults with uncontrolled COPD and evidence of type 2
u7xzq2r
REGN
31 May 24
and safety of Dupixent in adults with uncontrolled COPD with evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells per μL). All patients
yqrq40m40
REGN
31 May 24
studies that evaluated the efficacy and safety of Dupixent in adults with uncontrolled COPD with evidence of type 2 inflammation (i.e., blood
np5r6mx4xf99
REGN
31 May 24
. The potential use of Dupixent in COPD is currently under clinical development, and the safety and efficacy have not been fully evaluated by any regulatory
1333lcsatymvdebbylp84tpx2zeregcozcyyg7tre7xo110v08nslu
REGN
31 May 24
clinical development, and the safety and efficacy have not been fully evaluated by any regulatory authority. About the BOREAS and NOTUS
elzo19g8r ji10etog6bnt5j4wwkqoc63
BHVN
REGN
29 May 24
toxicity, that may translate to an improved clinical efficacy and safety profile
g7moz93k9rtx3l33 udynn6ms3v4iyczedmb4iivhb
REGN
23 May 24
cutoff. Safety was assessed in 84 patients across multiple solid tumor types at a variety of doses of REGN7075. REGN7075
few7ly3j2gr38v9z99chzdw 9bllvjn9ekfee3dzyausj40q4e1aivjqd0j
REGN
20 May 24
). The safety results were generally consistent with the known safety profile of Dupixent in its approved indications
y5djw6behfhr43yaw8wtxdbfq1aa7dinmjg4rp8wa2s8 fhpepkfnul1e1n
REGN
20 May 24
, as defined by PROs in Evaluating Respiratory Symptoms in COPD (E-RS). The safety results were generally consistent
xf5qi3sxyga6u2kdsmddd5he0l t85ljrrnvn8al9dwljksp7v3
REGN
13 May 24
supported by the safety data of Dupixent in its currently approved indications for adolescents. Safety results in both SINUS-24 and SINUS-52 were
2szq7z6uf5d88gawutyfzjqg4t cyyopa6lv
REGN
8 May 24
use of DB-OTO for otoferlin-related hearing loss is currently under clinical investigation, and its safety and efficacy have not been evaluated by any
1dpsud0jyez26ltryhrhlvmcroplcga8cgo3jznd5jfyzmrq5oorlqvn mx8
REGN
SNY
2 May 24
in healthy volunteers intended to demonstrate the safety of a higher dose of trevogrumab has completed enrollment.
Over 400
z1d4sreypt25a2jk ypcvym9bld58zzqcwe5xou2
REGN
2 May 24
/R FL and one for R/R DLBCL) did not identify any approvability issues with the clinical efficacy or safety, trial design, labeling, or manufacturing
6g1cno
REGN
29 Apr 24
extensive data presentations at ARVO showcase the differentiated efficacy, safety and durability of EYLEA HD, and demonstrate our commitment to advancing